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ABSTRACT

Bone deterioration is a challenge in long-term spaceflight with significant
connections to terrestrial disuse bone loss. Prolonged unloading and radiation exposure,
defining characteristics of space travel, have both been associated with changes in
inflammatory signaling via IL-6 class cytokines in bone. While there is also some
evidence for perturbed IL-6 class signaling in spaceflight, there has been scant
examination of the connections between free fall, radiation, and inflammatory stimuli in
bone. Our lab and others have shown that the IL-6 class cytokine oncostatin M (OSM) is
an important regulator of bone remodeling. We hypothesize that spaceflight alters
osteoblast OSM signaling, contributing to the decoupling of osteolysis and osteogenesis.
To test this hypothesis, we induced OSM signaling in murine MC3T3 E1 pre-osteoblast
cells cultured in modeled free fall, using a rotating wall vessel bioreactor, and with
exposure to radiation typical of a solar particle event. We measured effects on
inflammatory signaling, osteoblast maturation and activity, osteoclast recruitment, and
mineralization. There were time dependent interactions among all conditions in the
regulation of IL-6 production. OSM induced transcription of the OSM receptor β and
IL-6 receptor α subunits, collagen α1(I), osteocalcin, sclerostin, RANKL, and
osteoprotegerin. Measurements of osteoid mineralization suggest that the spatial
organization of the osteoblast environment is an important consideration in understanding
bone formation. Taken together, these results support a role for altered OSM signaling in
spaceflight bone loss.
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INTRODUCTION

Deteriorating bone health is a substantial barrier to human exploration deeper into
the solar system1. Each month in space, astronauts lose approximately 1% of the mineral
density in their weight-bearing bones2–5. Some of this loss may never be fully recovered
after return to Earth. The deterioration is likely to worsen during travel to Mars or nearEarth asteroids, when a fractured vertebra or femur could cripple the mission. These
missions could last two years or more, greatly extending the astronauts’ exposure to the
features of spaceflight most relevant to bone health: free fall and ionizing radiation.
While it is conventional to use the term “microgravity,” and somewhat less frequently
“weightlessness” and “zero gravity,” astronauts in the International Space Station (ISS)
experience 90% of the gravitational force at Earth's surface. Astronauts in free fall, and
their skeletons, are mostly experiencing unloading, the freedom from being compressed
against the ground3,6,7. While unloading is as characteristic of Earth orbit as it is for
interplanetary spaceflight, radiation exposure increases beyond low Earth orbit (LEO)8,9.
While ISS astronauts are exposed to little more radiation than they are on Earth, as one
moves beyond the shield of Earth’s magnetosphere, radiation exposure increases.
Galactic cosmic rays and solar particle events (SPE) become important sources of
radiation. Unpredictable SPE can rapidly deliver up to 2 Gy of radiation, comparable to
doses used in cancer radiotherapy to kill tumor cells8,10. There are also recognized clinical
parallels between spaceflight bone loss and disuse osteoporosis, a common complication
of inactivity from bed rest, immobilization, or sedentary lifestyle11–13. As the analogies to
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clinical radiation exposure and disuse osteoporosis suggest, addressing threats to bone
health from spaceflight may have significant benefits for the earthbound as well. To date,
efforts to counter deteriorating skeletal health in space have focused on resistive exercise
and nutrition, with limited success2–4,14. Space and weight constraints would likely further
limit exercise as an intervention beyond LEO. Taken together, these facts imply that
pharmacological countermeasures to bone loss will likely be required for exploration
deeper into the solar system. In turn, pharmacological interventions require understanding
the molecular pathways that induce bone loss in spaceflight, but these pathways are
poorly understood.
Bone is constantly broken down and replaced by a cyclical multicellular process
called the bone remodeling cycle15–19. Bone is calcified extracellular matrix (ECM)
produced by osteoblasts, specialized fibroblasts whose differentiation from mesenchymal
stem cells (MSC) is determined primarily by the transcription factor RUNX220. After
proliferation and additional maturation, marked by the transcription factor osterix21, the
osteoblast will produce osteoid, the organic component of the bone ECM. Osteoid is
primarily type I collagen. Additional components such as osteocalcin regulate the
mechanical and chemical properties of the bone22, including promoting the crystallization
of hydroxyapatite, the mineral component of bone. As the ECM is produced and matures,
some osteoblasts will become encased and terminally differentiate to osteocytes23. An
important function of the osteocyte is to limit the excessive formation of bone, largely
through the production of sclerostin24,25, a Wnt-signaling antagonist that potently inhibits
the maturation and activity of osteoblasts. When age or increased mechanical strain
damages bone, the osteoblast lineage cells initiate the bone remodeling cycle by
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recruiting osteoclasts26,27. Osteoclasts are multinucleate phagocytic cells specialized to
degrade and remove the damaged bone. They differentiate from myeloid precursors,
primarily under the influence of macrophage colony stimulating factor (MCSF) and
receptor activator of nuclear factor κB ligand (RANKL) produced by the osteoblast
lineage28. The osteoclasts are, in turn, closely followed by osteoblast bone replacement.
This is triggered by coupling factors that are not yet well defined29,30, but may involve
specialized osteal macrophages. This cycle normally carefully balances the extent and
location of removal and replacement to adapt to changing mechanical demands on the
bone. This mechanical sensitivity originates in the osteoblast lineage23,32.
Spaceflight leads to a decoupling of removal and replacement resulting in bone
loss. The available data suggest that this is characterized by a transient initial increase in
osteoclast activity followed by sustained decrease in osteoblast activity, but provide little
into the molecular mechanism involved3,5. The osteoblast lineage is likely central because
it is permanently present throughout bone and confers mechanical sensitivity. Somewhat
more detail is available on the osteoblast response to free fall and space radiation, largely
from ground-based models of spaceflight, although most mechanistic questions remain
unanswered3,32-34. The vast majority of these publications examine one factor in isolation;
very little is known about the combined effects of free fall and radiation. The disruption
of inflammatory cytokine signaling is an emerging feature of spaceflight with potential
relevance to these questions35–38. Ground-based experiments are showing changes in
inflammatory pathways39–41, as may have been expected from the alterations in
inflammatory signals seen in disuse osteoporosis11–13 and radiation exposure42–44.
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The bone remodeling cycle parallels wound healing, most obviously in the case of
a gross fracture, but also on the microscale45. Like in wound healing, inflammatory
cytokines are important signals in bone remodeling. Inflammatory cytokines are secreted
factors that coordinate cell behavior during inflammation. The IL-6-type cytokines are
an important group with broad effects in human health and disease, including in bone46.
They take their name from their prototypical member, interleukin-6 (IL-6). They are also
called the GP130 cytokines, after glycoprotein 130 (GP130), the receptor subunit shared
by all members of the class. GP130 is expressed by a wide array of cell types. Specificity
is achieved by the more limited expression of ligand-specific receptor subunits that work
in conjunction with GP130. All of the major cell types in bone express some combination
of GP130 cytokines and their receptors46, as do many of the immune cells produced in the
contiguous marrow space and involved in bone remodeling47,48. The cytokines with the
most demonstrated importance in bone are IL-6, leukemia inhibitory factor (LIF), and
oncostatin M (OSM). IL-6 signals through a complex comprising the IL-6 receptor α
subunit (IL-6Rα) and a homodimer of GP-130. LIF and most GP130 cytokines signal
through a complex of GP130 and LIF receptor α subunit (LIFRα), often with an
additional ligand-specific subunit46. OSM signals through either the LIFRα – GP130
dimer or a dimer of GP130 and the OSM receptor β subunit (OSMRβ). OSM is the focus
of research in our laboratory.
Some important discoveries have been made about the function of OSM in bone,
but the picture of its function in bone is far from complete. For some time, it has been
clear that OSM induces osteoblasts to secrete IL-649. The primary action of IL-6 in bone
is to amplify the generation and activation of osteoclasts50,51, and perception of OSM has
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been colored by the role of its better known relative. Indeed, OSM has been shown in cell
culture to promote osteoclastogenesis by inducing osteoblast RANKL expression and
reducing expression of osteoprotegerin52–55. However, it has also been shown that OSM
promotes differentiation and activation of osteoblasts, mineral formation, and represses
the expression of sclerostin49,56–59. In vivo data are complicated and suggest that some
effects are species specific60. Even in cell culture, OSM appears to have different actions
at different points in the osteoblast lineage59. Clearly many complications in the action of
OSM in bone remain to be illuminated.
The work presented here addresses two areas of uncertainty: the mechanisms of
bone loss in spaceflight and the function of OSM in bone. We hoped to shed light on both
questions by looking for interactions between them. Because OSM is known to act on
both the osteoblast lineage and through it the osteoclast, changes in its action could
account for many of the effects of spaceflight on bone. Defining a connection to
osteoblast mechanotransduction and radiation response would also contribute to our
understanding of OSM in bone. To this end, we hypothesize that spaceflight alters
osteoblast OSM signaling such that the decoupling of osteolysis and osteogenesis is
exacerbated.
To test this hypothesis, we examined the actions of OSM on GP130 signaling,
osteoclast recruitment, and osteoblast activity in a model of spaceflight. Our model
system used the MC3T3 E1 mouse pre-osteoblast cell line61 (MC3T3), which has been
shown to recapitulate important actions of OSM seen in primary cells57,62,63. To induce
OSM signaling, culture medium was supplemented with recombinant mouse OSM at 25
ng/ml. In one set of experiments, spaceflight was modeled by culturing cells on
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Cytopore-2 cellulose microcarriers in the NASA-developed Rotary Cell Culture System
(RCCS). This rotating wall vessel (RWV) type bioreactor models free fall through
gravitational vector averaging and low shear stress6,64. In deference to convention, this
condition is hereafter described as modeled microgravity (MMG). In an additional set of
experiments modeling exposure to a SPE, cell cultures were irradiated prior to culture in
MMG. The effect of these conditions on GP130 cytokines and receptors, osteoclast
recruitment, and osteoblast activity were then examined. Our results support the
hypothesis that spaceflight conditions alter the action of OSM signaling in osteoblasts.

7

MATERIALS AND METHODS

Cell Culture
The MC3T3 E1 subclone 4 mouse pre-osteoblast cell line61 and the UMR-106 rat
osteosarcoma cell line were obtained directly from the American Type Culture Collection
(Rockville, MD). MC3T3 cells were maintained in MEM (Life Technologies, Grand
Island, NY) supplemented to make α-MEM without ascorbic acid. All supplement
components were from Sigma-Aldrich (St. Louis, MO). UMR-106 were maintained in
DMEM (Hyclone, Logan, UT). All culture media were supplemented with 10% fetal
bovine serum and 100 U/mL each of penicillin and streptomycin. These supplements
were obtained from Hyclone (Logan, UT). Cells were maintained at 37 °C, 5% carbon
dioxide, and 95% humidity.

Microcarrier Culture
Cytopore 2 macroporous cellulose microcarriers were purchased from GE
Healthcare (Pittsburgh, PA). Microcarriers were hydrated in phosphate buffered saline
(PBS) at 20 mg/ml and autoclaved at 20 minutes at 121 °C. Microcarriers were rinsed
twice in sterile PBS then transferred to culture medium for at least 16 hours prior to
seeding cells.
To seed the microcarriers, MC3T3 E1 cells were grown to confluence,
trypsinized, and suspended in culture medium with microcarriers in a tissue culture flask.
Concentration of cells during seeding was 50,000 cells / ml and 5 mg microcarriers / ml.
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The mixture was agitated by gentle pipetting every 20 minutes for 3 hours and then
adjusted to 2 mg / ml. After seeding microcarriers were incubated as above, microcarriers
were agitated each morning and afternoon. Approximately one-half the medium was
replaced every three to four days. Experiments were initiated on the seventh day after
seeding.

Osteogenic Differentiation and Cytokine Stimulation
To induce osteogenic differentiation, MC3T3 cells were transferred to standard
α-MEM (Life Technologies) supplemented with an additional 50 μg/ml ascorbic acid and
5 mM phosphate buffer at pH 7.4. Mineralization medium was also supplemented as
above. Cells cultured on microcarriers had supernatant medium removed and replaced
with differentiation medium with mixing 3 times. To induce OSM signaling, culture
medium was supplemented with 25 ng/ml recombinant mouse OSM (R&D Systems).

Modeled Microgravity
The Rotary Cell Culture System (RCCS) and 10-ml high aspect ratio vessels
(HARVs) were purchased from Synthecon (Houston, TX). The RCCS is designed to
model free fall6,64. The HARV rotates around a horizontal axis so that medium and
microcarriers undergo solid body rotation, which averages the gravitational vector
experienced by cells to near zero. For Cytopore 2 microcarriers, a rotational speed of 18
rpm was found to be optimal by visual inspection. Oxygenation occurs through a gaspermeable membrane, preventing the formation of bubbles and ensuring smooth rotation
for the microcarriers.
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Modeled microgravity experiments lasted 7 days. At 12 h, 48 h, 96 h, and 7 days,
samples were collected for analysis. The culture medium was removed from the HARV.
After ensuring uniform suspension of the microcarriers, a portion of the medium was
retained so that the microcarriers would be evenly divided among the samples. The
remaining microcarriers were returned to the HARV along with fresh medium matching
the experimental condition. As controls at normal gravity, microcarriers were cultured in
tissue culture flasks at identical concentrations and volumes to the RCCS. Samples were
collected by the same procedure.

Radiation
MC3T3 cells were prepared on Cytopore 2 microcarriers as above.
Approximately 18 h prior to irradiation, cells were transferred to a sterile 50 ml conical
tube at a concentration of 2 mg Cytopore per ml. This concentration provides excess
culture medium. The tubes were then packed in an insulated, pre-warmed box with a 2 L
bottle of water at 37° C and shipped overnight to Dr. Jeffrey Willey, Radiation Biology
Section, Wake Forest University Medical Center. Tubes were exposed to 1 Gy at 364
rad/s from a 137Cs source. Tubes were repacked and return shipped overnight. Controls
were subjected to a sham irradiation procedure. Upon return, cells were immediately
transferred to mineralization medium and modeled microgravity or control conditions.
Samples were collected as described above at 12 h, 48 h, 96 h, and 7 days.

Semi-Quantitative Reverse Transcription Polymerase Chain Reaction
Microcarriers were allowed to settle in a conical tube and the supernatant medium
was aspirated. RNA was extracted using 1 ml RNA-STAT 60 (Tel-test Friendswood,
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TX) for each 1-2 mg microcarriers. After a 20 min. incubation, chloroform (200 μl/1ml of
RNA-STAT 60) was added followed by vortexing for 10 seconds, and centrifugation at
12,000rpm. The upper aqueous layer was transferred to a new tube containing
isopropanol (0.5ml/1ml of RNA STAT60), followed by vortexing for 10 seconds and
incubation on ice for 15 minutes. The mixture was centrifuged at 12,000rpm and the
supernatant discarded. The pellet was washed by adding 1ml of 75% ethanol, mixed and
centrifuged at 12,000rpm and the supernatant discarded. The RNA was allowed to airdry in a sterile environment and resuspended with nuclease free water.
cDNA was generated from this RNA using a commercially available reverse
transcriptase kit (Applied Biosystems) per manufacturer instructions. The cDNA
generated from the reverse transcription reaction was used in a 25 μl PCR reaction
containing 2.5 μl of 10x PCR buffer, 2.5mM dNTPs, 10mM primers, 5U GoTaq
polymerase (Promega, Madison, WI) and 2 μl cDNA. Amplifications were carried out as
follows: initial denaturation at 95°C for 2 minutes, followed by the indicated number of
cycles of 95°C for 1 min, annealing temperature for 1 min, 72°C for 1 min, then a final
extension of 72°C for 10 minutes. Primer pairs and reaction conditions for each target are
provided in Table 1. The PCR products were electrophoresed on a 1% Tris-Agarose gel
containing 0.5 μg/ml of ethidium bromide at 80 volts for 45 minutes. The gels were
imaged using a Kodak Image station and exposed for 10 seconds. Band densities were
calculated using the ImageJ software (NIH) and normalized to GAPDH. For RT-PCR
analyses, the sample size was 4.
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Enzyme-Linked Immunosorbent Assay
To measure secreted IL-6, conditioned medium was collected from each sample
collected above. IL-6 was quantified with the mouse IL-6 DuoSet kit from R&D
Systems according to the manufacturer’s instructions. Plates were washed with PBS at
pH 7.4 containing 0.05% Tween-20 (PBS-T) and blocked using PBS containing 1% IgGfree BSA (Jackson Immunological West Grove, PA). The substrate used was Thermo
Pierce (Rockford, IL) 1-Step Ultra TMB. A seven point standard curve was prepared by
serial dilution of the included 1000 pg/ml standard. Sample concentrations were
interpolated from a 4 parameter logistic fit of the standards. All samples and standards
were assayed in duplicate. All ELISA analyses have a sample size of 3.

Alizarin Red Staining
For monolayer experiments, MC3T3 cells were cultured in mineralization
medium for 6 or 14 days in 12-well plate. For microcarrier experiments, a 2 mg sample
was retained from each MMG and MMG with radiation experiment and cultured for an
additional week in experimental conditions. Medium was aspirated and the cells were
washed once with PBS, then fixed in 10% formalin for 15 minutes. Formalin was
aspirated and the cells were washed three times with deionized water. Four-hundred μl of
40 mM alizarin red (Millipore, Billerica, MA) was added to each sample. After a 20
minute incubation at room temperature, the stain was aspirated and the cells were washed
four times with deionized water.
For extraction and spectrophotometric quantification, 400 μl 10% acetic acid was
added to each well. The matrix was disrupted with a pipette tip in monolayer or
trituration in microcarrier experiments. The sample was then transferred to (or retained
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in) a micro-centrifuge tube and incubated for 30 min at 85°C. Tubes were then
transferred to ice for 5 minutes, then centrifuged 20 minutes at 16,000xg. Ten standards
were prepared by serial dilution from 4 mM alizarin red. Samples and standards were
adjusted to pH 4.2 with 10% ammonium hydroxide. One hundred μl of each sample and
standard was transferred in duplicate to a 96-well plate and the absorbance read at 405
nm. Sample concentration was calculated by comparison to a linear least-squares best fit
of the standards.
For quantification by confocal microscopy and densitometry, a microscope slide
of the sample was prepared after washing but before the extraction procedure. The
sample was imaged on a Zeiss LSM 510 Meta system combined with the Zeiss Axiovert
Observer Z1 inverted microscope and ZEN 2009 imaging software (Carl Zeiss, Inc.,
Thornwood, NY). Excitation was at 540 nm and emission was measured at 580 nm. A
sample of at least 20 microcarriers was imaged under identical settings with intensity at
580 nm saved as 8-bit grayscale. Using the ImageJ software (NIH), thresholding was
applied at 30/255 to eliminate background, then the integrated intensity of each image
was calculated. Integrated intensity per bead was calculated and used to represent alizarin
red staining.

Statistics
MMG experiments were analyzed using three-way analysis of variance
(ANOVA) with repeated measures of each combination of MMG and OSM induction
(corresponding to a culture vessel) at each level of time. MMG with radiation
experiments were analyzed using four-way ANOVA with repeated measures of each
combination of radiation, MMG, and OSM induction (corresponding to a culture vessel)
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at each level of time. Multiple comparisons were conducted with Tukey's HSD test post
hoc. Each response variable was treated separately. For all comparisons, α = 0.05. In
figures, bars and asterisks (*) indicate p < 0.05 for the indicated main effect. Any
interactions identified in the test had a p < 0.05. Calculations were performed in the R
statistical environment (R Project).

14

RESULTS

OSM and MMG Synergistically Induce IL-6 Secretion
To assess the action of osteoblast OSM signaling in MMG, we first examined the
transcription of the cytokines and receptors most closely associated with OSM by semiquantitative reverse transcription polymerase chain reaction (RT-PCR) (Fig. 1A). OSM
supplementation was observed to induce the transcription of OSMRβ (Fig. 1B) and IL6Rα (Fig. 1C). Induction of the receptors reached its peak at 48 h and remained stable
afterward. These effects of OSM have not been previously described in osteoblasts.
MMG had no statistically significant effect on these targets.
IL-6 was the most substantially affected of the examined transcripts (Fig. 1D).
Both OSM supplementation and MMG independently induced IL-6 transcription, which
is consistent with prior results49,65 . Additionally, the combination of OSM
supplementation and MMG (hereafter OSM+MMG) increased IL-6 transcription by more
than twice what would be expected from even multiplicative combination of their
individual effects, reaching 70-fold by 7 d. This synergistic effect has not previously been
described. OSM's effect was seen as early as 12 h after treatment and increased
throughout the 7 d. The independent effect of MMG was not observed until 48 h and
remained stable afterward. The synergistic effect from OSM+MMG was detected from
48 h, along with the effect from MMG alone. The amplification of IL-6 induction
demonstrates for the first time that MMG does alter the effect of OSM signaling.
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To ensure that the effects of OSM signaling induction and MMG extended to the
secretion of the IL-6 protein, we tested the cell culture conditioned medium using ELISA
(Fig. 2). Again, both OSM supplementation and MMG were shown to independently and
synergistically induce osteoblast IL-6 production, with the effect of MMG lagging OSM
in both time and scale. OSM alone increased secretion by as much as 200-fold over
control conditions, while the effects of MMG on mRNA and secreted protein were
proportional at 48 h. The fold increase in secreted protein was much larger than the
transcriptional change. This may reflect the accumulation of protein in the culture
medium as IL-6 was produced at increasing rates. It is also possible the at posttranscriptional regulatory effects account for difference. Regardless, the interaction of
MMG and OSM is confirmed at the protein level. This supports the hypothesis that
spaceflight alters OSM signaling in the osteoblast.

Radiation Limits the Effect of OSM Induction on IL-6 Secretion
but Enhances the Effect of MMG
The action of OSM signaling on osteoblast inflammatory factors was next
examined in the context of a more complete model of spaceflight including both MMG
and radiation typical of a solar particle event (SPE). Statistically significant interactions
(p < 0.01) between OSM signaling and these spaceflight conditions were again observed
in the regulation of IL-6 production. Radiation had no significant additional effect on any
other targets assessed by RT-PCR (Table 2). The changes in IL-6 mRNA measured by
RT-PCR were entirely reflected in the measurements of secreted IL-6. A general increase
in the concentration of IL-6 compared to the experiments without radiation is attributed
to the increase in Cytopore microcarrier concentration from 4 mg/ml to 4.5 mg/ml,
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increasing the number of cells, and the fewer time points at which samples were
collected, decreasing the dilution of the conditioned medium with fresh medium. Both
changes were made to provide sufficient cell numbers for the additional experimental
factor. Sham irradiation control recapitulated the effects of the RCCS-only model with its
substantial synergistic increase in secretion (Fig. 3A, left column), validating the
radiation procedure. As in the experiments without radiation, OSM increased IL-6
secretion by at least 10-fold under all conditions. Consequently, to facilitate comparison
of other conditions, the results of the experiments with radiation are separated into panels
showing results without-OSM (Fig. 3B) and with-OSM (Fig. 3C).
Intriguingly, the effects of radiation in combination with either OSM
supplementation were opposite of the effects of radiation alone or radiation with MMG.
Radiation alone increased IL-6 secretion relative to the control at 48 h and 7 d by
approximately 5-fold, confirming a response recently reported for the first time in
osteoblasts43 (Fig 3B). Radiation in combination with MMG increased the secretion of
IL-6 relative to either factor alone. The scale of this increase compared to multiplicative
combination of the factors was approximately two-fold, comparable to the synergistic
effect seen from OSM+MMG in absence of radiation. Contrary to these increases in IL-6
secretion, irradiation decreased the effect of OSM supplementation at all time points by a
substantial margin, approximately 50% (Fig 3C). Finally, radiation did not change the
induction of IL-6 by OSM+MMG except at 12 h, when all conditions respond as if MMG
were not present. Considered together, these complicated interactions again support the
action of spaceflight conditions on OSM signaling.
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OSM Counteracts the Effect of MMG on the RANKL:Osteoprotegerin Ratio
It has been observed that IL-6 functions primarily in bone to magnify osteoclast
recruitment and activity50,51. OSM is also known to enhance RANKL expression and
osteoclast activation52,54,55. To determine if spaceflight conditions also interact with these
actions of OSM, we measured the transcription of the osteoblast-produced factors most
important for osteoclastogenesis: MCSF, RANKL, and osteoprotegerin (Fig. 4A). We
found that RANKL (Fig. 4B) was upregulated by MMG. MMG alone also decreased the
transcription of osteoprotegerin, so that the ratio of RANKL to its decoy receptor would
be increased, which favors increased osteoclastogenesis. In these experiments, OSM did
not exert a statistically significant effect on RANKL expression, but there was a clear
interaction between OSM signaling induction and MMG. When the two were present in
combination, osteoprotegerin mRNA levels increased proportionally to the increase seen
in RANKL, so that in this case the RANKL:OPG ratio would be preserved. The
implication is that the osteoblast recruitment of osteoclasts in free fall may depend on the
absence of OSM signaling.

OSM and MMG Have Independent and Opposing Effects on Osteoblast Activity
To determine if the interdependence of osteoblast OSM signaling and MMG
extended to their effects on osteoblast maturation and activity, we analyzed samples
collected over the course of a week in these conditions by semi-quantitative RT-PCR for
several markers of osteoblast differentiation and osteoid production (Fig. 4A). Significant
effects were found for collagen α1(I) (Fig. 4B), osteocalcin (Fig. 4C), and sclerostin (Fig.
4D). Independently, OSM and MMG acted on collagen α1(I) and osteocalcin, as would
be expected for these components of osteoid and markers of middle and late osteoblast
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maturation. Both had mRNA levels increased by OSM and decreased by MMG.
Sclerostin was increased by MMG, suggesting an increase in the osteocyte character of
these cell cultures and consistent with evidence that free fall inhibits osteoblast
differentiation. No significant interaction between these factors was detected by
ANOVA, which suggests that spaceflight does not alter the effect of OSM on osteoblast
activity.

RCCS and Cytopore Cell Culture Does Not Model Spaceflight's Effect
on Osteoid Formation and Mineralization
The effect of OSM on the production of mineralized osteoid was also
investigated. The organic dye alizarin red specifically stains mineralization in osteoid
(Fig. 6A), allowing visualization of the differences in osteoid production in cell culture.
The dye can also be extracted and quantified spectrophotometrically66. This aided in the
choice of the MC3T3 E1 cell line to study OSM's effect in osteoblasts. The MC3T3 E1
cell line was chosen for these experiments in part because of the clear effect OSM has on
culture mineralization, whereas the UMR-106 rat osteosarcoma cell line, for example,
shows no effect (Fig. 6b). A different approach to mineral quantification was used for
MC3T3 cells cultured on Cytopore microcarriers when the extraction technique proved
insufficiently sensitive. Because alizarin red fluoresces when excited by light at 530-560
nm, staining could be visualized with laser confocal microscopy (Fig. 6C). It proved
possible to quantify the staining by densitometry, and thus mineralization, on samples of
microcarriers (Fig. 6D and F). While reproducible, the results from this technique showed
substantially higher mineralization in MMG (Fig. 6F), not at all consistent with the
effects of spaceflight2,3. During staining, large quantities of what proved to be
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mineralizing material were sometimes noted (Fig. 6E). This material—here called extravehicular mineralization (EVM) and presumed to be osteoid—was only found in normal
gravity control cultures, never in samples from the RCCS. It appears the microcarriers
must be stationary for the osteoblasts to produce EVM. In the control gravity samples, the
EVM was generally disrupted and lost during staining and washing, so that most of it
could not be quantified. When the remnant EVM was quantified, however, it
substantially exceeded the mineral found on only the microcarriers from the same
samples (Fig. 6F). From these observations, we conclude that the RCCS model of free
fall used with Cytopore microcarriers is unable to reproduce the patterns in mineral
formation seen in actual spaceflight data.
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DISCUSSION

Understanding how spaceflight disrupts the bone remodeling cycle is important
for human space exploration and likely to improve health on Earth. The many
uncertainties in skeletal physiology are an obstacle to that understanding. Among these
uncertainties is the incomplete picture of the action of inflammatory signaling in the
regulation of bone remodeling. The results presented here connect the questions of
spaceflight's action in bone and the function of the GP130 cytokines. In particular, they
support the hypothesis that free fall and ionizing radiation alter the function of OSM
signaling in bone. The pattern seen in the disruption of the effects of OSM is consistent
with a contribution to the increase in osteolysis and decrease in osteogenesis seen in
astronauts.
The most prominent effect of our model of spaceflight on osteoblast OSM
signaling was on GP130 signaling itself, particularly the secretion of IL-6. We described
here an increase in IL-6 secretion by MMG and the synergistic increase by the
combination of MMG and OSM supplementation. The increase in secretion is closely
paralleled by an increase in IL-6 mRNA. The degree of increase in IL-6 secretion cannot
be explained by a simple combination of the individual effects of MMG and OSM. This
is clear evidence that the one effects the other. One possible explanation for this is that
MMG interferes with feedback inhibition mechanisms regulating OSM signal
transduction or IL-6 secretion. Inhibition of OSM and IL-6 signaling by suppressor of
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cytokine signaling (SOCS) protein is an example of an important regulatory pathway that
is known to be involved in skeletal health and could be inhibited in spaceflight67,68. As
IL-6 acts in bone to increase the recruitment of osteoclasts50,51, this increase in IL-6
secretion can reasonably be expected to contribute to osteolysis in spaceflight. This is
particularly significant considered alongside the data collected from astronauts
suggesting that GP130 signaling is generally altered in spaceflight and IL-6 levels
increased in particular35–38. While not dependent on MMG, the observed increase in
OSMRβ and IL-6Rα mRNA is consistent with a positive feedback mechanism for OSM
and IL-6 signaling that may be important in understanding the general action of these
cytokines in bone.
OSM's regulation of osteoblast IL-6 secretion is further complicated in a
spaceflight model that includes radiation. Radiation alone or in combination with MMG
increased IL-6 secretion, as did OSM treatment. Radiation in combination with OSM,
however, diminished the OSM induced secretion by as much as half. Possibly relevant to
this effect is a pattern of dose dependence in the response of osteoblasts to ionizing
radiation. Exposures at less than 2 Gy, promote osteoblast differentiation and osteoid
production69–71. Radiation above this level has the opposite effect43,71–74. Yumoto et al.
have also observed that the combination of irradiation with unloading may also determine
the effect of ionizing radiation on osteoblast function75, as we observed here. Applying
these observations to our data, it is reasonable that the combined effect of OSM and
radiation differs from their individual effects. It is possible, for example, that the
combination of radiation and OSM supplementation at receptor-saturating concentrations,
as we used here, crosses a threshold that triggers a protective quiescence in the osteoblast,
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similar to the response to high dose radiation described by Kansara et al.43 It is also
noteworthy that factors other than dose affect osteoblast response to radiation. Linear
energy transfer (LET) may be an important factor42,76,77, which should be considered in
evaluating our model, which only uses low-LET photons. The radiation from SPE and
GCR in spaceflight has a large high-LET component8. As we have shown, many factors
must be considered in any attempt to understand the osteoblast response to radiation.
In summary, OSM supplementation, modeled free fall, and radiation all
independently increase the secretion of IL-6. OSM has the largest and most immediate
effect. Free fall and radiation both a have more modest effect on IL-6 secretion that
presents more slowly than the effect from high levels of OSM supplementation. The
difference in timing may only be apparent, due to the inability of our assays to detect the
comparatively smaller early effects, or it may indicate that OSM acts more directly on IL6 transcription than free fall or radiation. These explanations are not mutually exclusive.
We have also described a dependence on MMG for the action of OSM on
osteoblast-mediated osteoclast recruitment. In control gravity conditions, active OSM
signaling had no effect on the RANKL:osteoprotegerin ratio. In MMG, OSM signaling
increased osteoprotegerin levels. On its own, this is further evidence that free fall alters
the action of OSM signaling in the osteoblast, which supports our central hypothesis. It
also demonstrates that MMG depends on the presence or absence of other factors for its
effects. By implication, the effect of free fall on astronauts may depend on factors that
vary between individuals, such as baseline inflammatory cytokine levels. It cannot be
determined from these experiments how this feature of OSM signaling in MMG, which
would oppose increased osteoclastogenesis, balances with the increase in IL-6 secretion
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and its support of osteoclast recruitment. Although these experiments did not support
spaceflight acting through OSM signaling to affect osteoblast activity and maturation, it
is worth noting that they focused on the already osteoblast-committed MC3T3 cell line.
OSM is known to act throughout the osteoblast lineage from uncommitted precursors to
osteocytes59,78,79. One can imagine that spaceflight would alter the effect of OSM
signaling at these other points in the osteoblast lineage. Another possibility is that
spaceflight conditions alter the effect of OSM signaling on osteoblast activity, but that
these experiments could not detect the effect. Comparatively small effects or posttranslational interactions, for example, would not be detected by semi-quantitative RTPCR. Our results do imply that inflammatory signaling pathways must be considered in
understanding the action of spaceflight on osteoclast activity.
The overall picture present here is this: Free fall and radiation act independently
of OSM to increase osteoblast-mediated osteoclastogenesis through both the RANKL –
osteoprotegerin system and IL-6 production. Meanwhile, free fall inhibits the activity of
osteoblasts, leading to an increase in osteolysis and decrease in replacement with new
bone. Additionally, free fall synergizes with OSM to increase IL-6 production further
without any balancing effect on osteoblast activation, so that the overall effect of OSM
on the osteoblast in space may be to promote bone loss. Thus spaceflight may act through
OSM signaling to unbalance the bone remodeling cycle. This interpretation of our results
is summarized graphically in Figure 7.
It is worthwhile to consider the inability of this system to model changes in
osteoid production and mineralization in spaceflight. EVM could not form in MMG, most
likely due to the microcarriers' constant motion. The ability of the osteoblasts to move
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beyond the microcarrier appears to have been critical for the organization and amount of
osteoid they produced. That ability to move and interact in a larger space may also have
been critical in successfully modeling the decrease in osteoblast activity seen in
spaceflight. Bone is a complex tissue, where many effects depend on the spatial and
temporal interaction of many different cells. It is difficult to predict which features of that
complexity will be important for a given question, in bone or anywhere in biology. The
most valuable contribution of this work may be pointing to GP130 signaling as a feature
that must be included in a complete picture of bone in space.
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Table 1:

PCR Primers and Reaction Conditions

Target
GAPDH
OSM
OSMRβ
LIF
LIFRα
IL-6
IL-6Rα
MCSF
RANKL
osteoprotegerin
RUNX2
osterix
collagen I(α1)
osteocalcin
sclerostin

Fwd. Primer
Rev. Primer
ATCACTGCCACCCAGAAGAC
GGTCCTCAGTGTAGCCCAAG
AGCAAGCCTCACTTCCTGAG
GTGGGCTCAGGTATCTCCAG
TAGACTGAACATATCCAACACCA
TCCATGGATTGGCTCATCTGGCA
CAGACAGACAGGTAGCATAAAG
GACACAGAGACAGACAGAGA
GAAAACTGTAAGGCGCTACA
CCAAGTGTTTACATTGGC
CCTCTGGTCTTCTGGAGTACCAT
GGCATAACGCACTAGGTTTGCCG
CCAGGTGCCCTGTCAGTATT
CCGTGAACTCCTTTGACCAT
CGACTTCCCGTAAAGGCATAAA
CAAGGAACACAGCCCAAAGA
GAGAGGTATTCCGATGCTTATG
GGTGACCAACATCCTACTTATT
AGAGTGAGGCAGGCTATT
AGTAGTTTCTTCTGGTGCTATG
CCCTTCCTCTTCCCTTATCTCT
GTGCTTCTGCTACCACTCTAAC
CTGCTTGAGGAAGAAGCTCACTA
GGGGAGCAAAGTCAGATGGG
AACAAGGTGACAGAGGCATAAA
GCTGCGGATGTTCTCAATCT
GACCATCTTTCTGCTCACTC
TTGCACTTCCTCATCTGAAC
TTCCACCCAAATGTAAAGCCTGCG
ATTTCTGGCCCTTCCACCATCTCT

Prod.
Size

Temp.
cDNA
Cycles
(ºC)
dilution

202

57

30

1:10

200

60

35

1:1

349

60

30

1:1

487

60

35

1:1

483

52

35

1:1

307

55

30

1:10

317

60

35

1:1

530

60

30

1:1

577

60

35

1:1

511

60

35

1:1

509

60

35

1:1

490

60

35

1:1

440

60

30

1:10

425

60

35

1:1

366

60

35

1:1
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Table 2:

Summary of Semi-Quantitative RT-PCR

Mean relative expression at 48 hours by densitometry (arbitrary units) where significant
by ANOVA. NC indicates no significant change.
OSM

-

+

-

+

-

+

-

+

MMG

-

-

+

+

-

-

+

+

Radiation

-

-

-

-

+

+

+

+

OSM

NC

NC

NC

NC

NC

NC

NC

NC

OSMRβ

0.913

1.338

0.857 1.330

0.942 1.325

0.822 1.350

LIF

NC

NC

NC

NC

NC

NC

NC

NC

LIFRα

NC

NC

NC

NC

NC

NC

NC

NC

IL-6

1.097

13.739 1.834 36.876 1.000 20.271 2.763 88.308

IL-6Rα

1.438

2.038

1.082 2.107

1.424 2.080

1.124 2.235

MCSF

NC

NC

NC

NC

NC

RANKL

0.835

0.980

1.131 1.288

0.937 0.843

1.219 1.291

osteoprotegerin 0.962

1.005

0.760 1.347

0.851 1.110

0.675 1.247

RUNX2

NC

NC

NC

NC

NC

NC

NC

NC

osterix

NC

NC

NC

NC

NC

NC

NC

NC

collagen α1

0.960

1.255

0.603 1.119

1.048 1.360

0.725 1.204

osteocalcin

0.977

1.226

0.602 1.033

0.939 1.192

0.729 1.115

sclerostin

0.832

0.605

1.399 1.209

0.816 0.550

1.151 1.105

NC

NC

NC
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Figure 1.
OSM and MMG independently and synergistically induce the
transcription of IL-6.
MC3T3 pre-osteoblasts were cultured with OSM supplementation and MMG for
7 days. RNA was collected at 12 h, 48 h, and 7 d. Semi-quantitative RT-PCR was
conducted for the cytokines and receptors most closely associated with OSM in
osteoblasts, listed in (A) with representative images from 48 h, when effects were seen
for the largest number of targets. (B-D) Scatter plots of the densitometry results showing
the mean and standard error of the mean (SEM) for the targets with statistically
significant regulation by OSM or MMG (arbitrary units). OSM alone induced the (B)
OSMRβ and (C) IL-6Rα subunits, shown at 48 h, when the largest effect was seen. (D)
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IL-6 was induced independently by both OSM and MMG. Induction by OSM alone
progressed from approximately 5-fold at 12 h to 20 fold at 7 d. Induction by MMG was
first significant after 48 h and remained stable afterward at approximately 2-fold. The
factors interacted significantly to amplify their independent effect, inducing IL-6
transcription approximately 35-fold at 48 h and 70-fold at 7 d.

Figure 2.
IL-6.

OSM and MMG independently and synergistically induce secretion of

MC3T3 pre-osteoblasts were cultured with OSM supplementation and MMG for
7 d. IL-6 secretion was measured in conditioned medium by ELISA; scatter plots show
mean and SEM. OSM treatment induces secretion of IL-6 at all time points with a 7-fold
induction at 12 h increasing to 200-fold by 7 d. A 2-fold increase in IL-6 secretion by
MMG is significant at 7 d, but may be present earlier. The synergistic effect of OSM and
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MMG on IL-6 secretion is first significant at 48 h at approximately 350-fold. It increases
to approximately 500-fold at day 7.
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Figure 3.
Radiation limits the effect of OSM induction on IL-6 secretion but
enhances the effect of MMG.
MC3T3 cells were cultured in a spaceflight model combining culture in the RCCS
and radiation representative of a SPE (1 Gy at 364 rad/s from a 137Cs source). Osteoblast
IL-6 secretion was measured by ELISA and are shown as scatter plots with mean and
SEM. An overview of these data is shown in (A). The effects of OSM and MMG on IL-6
secretion were unaffected by sham irradiation (A, left column). Under all conditions,
OSM treatment induced IL-6 secretion by at least 10-fold. Consequently, radiation and
MMG effects are broken out into control (B) and OSM treated (C). In the absence of
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OSM treatment (B), irradiation alone increased IL-6 secretion relative to sham irradiation
by approximately 5-fold from 48 h on. The combination of MMG and radiation
treatments (without OSM treatment, B) magnified the induction of IL-6 approximately
10-fold compared to MMG treatment alone. With OSM treatment (C), irradiation without
MMG decreased IL-6 secretion at all time points. Irradiation had no effect on the
synergistic increase in IL-6 secretion seen with combined OSM induction and MMG. For
clarity, statistical results are shown only in (B) and (C).

Figure 4.
ratio.

OSM counteracts the effect of MMG on the RANKL: Osteoprotegerin

Semi-quantitative RT-PCR was used to examine the interaction of OSM and
modeled free fall on the osteoblast transcription of MCSF, RANKL, and osteoprotegerin.
(A) Representative images from samples collected after 48 h, when the most significant
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effects were seen for RANKL and osteoprotegerin. No changes were detected for MCSF
or with radiation for any of these targets. Significant effects when quantified by
densitometry are shown as scatter plots with mean and SEM for RANKL (B) and
osteoprotegerin (C). RANKL transcription increased under MMG (B), without an
associated increase in osteoprotegerin (C). The combination of OSM and MMG,
however, increased osteoprotegerin proportionally to the increase in RANKL.

Figure 5.
activity.

OSM and MMG have independent and opposing effects on osteoblast

Markers of osteoblast maturation and activity were assessed by semi-quantitative
RT-PCR for interactions between OSM signaling and MMG. Representative images at 48
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h are shown (A), when the largest effects were found. For markers affected by OSM or
MMG, the results of densitometry are shown as scatter plots with mean and SEM (B-D).
OSM supplementation induced collagen α1 (B) and osteocalcin (C) transcription, but had
no significant effect on sclerostin transcription (D). MMG inhibited the transcription of
collagen α1 and osteocalcin, while increasing transcription of sclerostin. No significant
interaction between the factors was detected by ANOVA.

Figure 6.
RCCS and Cytopore cell culture does not model spaceflight's effect on
osteoid formation and mineralization.
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(A) Alizarin red staining of osteoid mineralization after culture of MC3T3 cells
for 6 or 14 days in mineralizing culture medium. OSM increases production of
mineralizing osteoid. (B) Quantification of the differential effect of OSM on
mineralization after 14 d in monolayer culture for the MC3T3 mouse pre-osteoblast and
UMR-106 rat osteosarcoma cell lines. (C) Confocal micrograph (400x) of fluorescent
alizarin red bound to mineralization in MC3T3 culture on Cytopore microcarriers. (D)
Representative confocal micrograph (50x) of MC3T3 cultured 14 d on Cytopore with
mineralization stained for quantification by densitometry. (E) Confocal micrograph (50x)
of Cytopore MC3T3 culture in control gravity conditions showing extra-vehicular
mineralization (EVM). (F) Densitometry showed greater mineralization in MMG
cultures. (G) EVM accounts for the majority of mineralization under control gravity
conditions.
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Figure 7.

Spaceflight conditions act on bone through OSM signaling.

In normal circumstances (left), OSM signaling has a balanced effect on osteoblast
activity and osteoclastogenesis. In spaceflight (right), it is possible that this balance is
disrupted. The synergistic increase in IL-6 secretion increases osteoclastogenesis.
Meanwhile, there is no matched synergism in the action of OSM on osteogenesis. This
leads to an increase in net bone loss.
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